Format

Send to

Choose Destination
Respir Physiol Neurobiol. 2008 Jan 1;160(1):116-21. Epub 2007 Aug 26.

Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model.

Author information

1
MP3-Respiration, UMR CNRS 6153, 280 Boulevard Sainte Marguerite, 13009 Marseille, France.

Abstract

Rett syndrome is a neurodevelopmental disease due to Mecp2 gene mutations that is associated to complex neurological symptoms, with bioaminergic deficits and life-threatening apneas related to sudden and unexpected death. In male mice, Mecp2-deficiency similarly induces medullary bioaminergic deficits, severe apneas and short life span. Here, we show that long-term oral treatment of Mecp2-deficient male mice with desipramine, an old drug of clinical use known to block norepinephrine uptake and to strengthen its synaptic effects, significantly alleviates their breathing symptoms and prolongs their life span. Although these mouse results identify desipramine as the first oral pharmacological treatment potentially able to alleviate breathing symptoms of Rett syndrome, we recommend further studies of desipramine effects in Mecp2-deficient mice before attempting any clinical trials in Rett patients.

PMID:
17905670
DOI:
10.1016/j.resp.2007.08.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center